2015 Access Data Epilepsy 
NORML
AUGUST 26, 2019
So, it shouldn’t be a huge surprise that Virginia didn’t launch a medical marijuana program until 2015, nearly two decades after California. Not much happened between 1979 and 2015, aside from preventing the repeal of the wonky 1979 law. As in, no to anyone who wasn’t an epilepsy patient.].
Canna Care Docs
DECEMBER 16, 2020
The difference is that medical patients may have access to higher dosages, among other benefits depending on their state, and receive a higher level of service to match them with the best products for their symptoms. Research is ongoing, but the existing data and anecdotal reports show potential. Nausea and vomiting.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
NOVEMBER 24, 2021
However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. At the same time, the outlook on cannabis research data is largely positive. Refractory paediatric epilepsy.
Veriheal
MAY 31, 2022
According to data released by the Centers for Disease Control and Prevention , there were an estimated 2,620 opioid overdose deaths in Texas between Aug. The state legalized medical cannabis in 2015 via the Texas Compassionate Use Act , but very few residents qualified to use it for treatment. Expanded Qualifying Conditions.
Veriheal
OCTOBER 5, 2020
The qualifying conditions for medical cannabis has been established in the bill as follows: Amyotrophic Lateral Sclerosis (ALS), Cachexia, Cancer, Chronic Pain, Crohn’s Disease, Epilepsy, Glaucoma, HIV/Aids, Lupus, Multiple Sclerosis, Nausea, Persistent Muscle Spasms, Post-traumatic Stress Disorder (PTSD), Rheumatoid Arthritis. .
Cannabis Law Report
DECEMBER 9, 2019
Up until December of 2015, regulatory limitations put in place by the FDA prohibited researchers from conducting CBD-related trials in the US. However, as reported by New Frontier Data reports, there are two selling points that are overwhelmingly driving growth: reducing anxiety and reducing inflammation. Why so little research?
Greencamp
AUGUST 16, 2018
The CBD cannabinoid is proven to be an exceptional seizure-controlling agent for epilepsy patients, and also shows great promise for treating Parkinson’s , Alzheimer’s and Multiple Sclerosis. Marijuana and Epilepsy: Here’s How Cannabis Stops Seizures (12 Studies). Exploring the available research on ALS and cannabinoids.
Expert insights. Personalized for you.
208 
Let's personalize your content